Intertek announces the expansion and relocation of its bioanalytical LC-MS facility

The relocation to the San Diego facility will be completed by June 2015. The increased laboratory capacity of the San Diego facility, which spans 46,000 square feet of laboratories, offices and sample storage, will benefit customers involved in preclinical and clinical small molecule drug development. This will be coupled with investment in new state-of-the-art mass spectrometers which will be operational at the new San Diego LC-MS facility prior to relocation and so avoid service delivery interruption.

Existing large molecule bioanalysis services from the immunochemistry laboratory in San Diego will be strengthened by expanded capability for bioanalytical LC-MS evaluation of biologic drugs such as proteins, antibody therapeutics or biosimilars as a result of the relocation and investment.

Chetan Parmar, Senior Vice President of Intertek Life Sciences, said “Expanding and consolidating our bioanalytical capacity will strengthen our capability to address the challenges our clients encounter during increasingly complex drug development programs and provide them with the right data for informed decision-making".

Intertek has been providing Good Laboratory Practice (GLP) compliant bioanalytical services to global pharmaceutical clients supporting their preclinical and clinical studies for over 20 years and the combined bioanalytical LC-MS/immunochemistry facility will be a key part of Intertek’s network of state-of-the art GLP-compliant laboratories.